(Information sent by the signatory company)
MADRID, Nov. 23, 2022 /PRNewswire/ — Affidea, Europe’s largest provider of advanced diagnostics, cancer treatment and outpatient services, is pleased to announce that the company has won the LaingBuisson Health “Diagnosis and Primary Care” award from this year.
The LaingBuisson Awards are one of the most prestigious accolades in healthcare, honoring companies that set new standards of excellence and make an impact in their category. This year marks the 17th year of recognizing excellence in healthcare, focusing on healthcare providers and their advisors.
Affidea has won the award in this category for its innovative Dose Excellence Program for patient safety. Through this program, the company analyzes information from more than 75,000 computed tomography (CT) scans each month, achieving an average reduction of 40% in the radiation dose level in CT scans across its network, to increase patient safety maintaining image quality for accurate diagnosis.
Affidea has recently taken the program to the next level with the release of a version 3.2 of DoseWatch software, in combination with a real-time business intelligence (BI) tool for building data dashboards. , being the Affidea centers in Spain and Hungary the first to implement it.
The next step of the project is contrast media data management, which allows you to receive notifications about the clinical setting and cumulative iodine dose (risk factors, previous adverse events), as well as injection details (contrast media). contrast, volume, injection protocol). By monitoring and optimizing the contrast media, the company can customize the contrast injection for each patient, avoiding unnecessary extra contrast injection.
Guy Blomfield, Chairman of the Supervisory Board and CEO of Affidea, states: “It is an honor to receive this prestigious award. This is a testament to all our efforts and achievements in delivering exceptional patient safety, implementing strict clinical protocols and innovative tools. I want to thank all of our amazing and dedicated clinic teams, and especially the Dose Excellence team members, for all their passion, commitment and hard work behind the scenes.This award recognizes the very high quality of their work and I couldn’t be more proud of this.”
Dr. Alessandro Roncacci, Senior Medical Director, adds: “This is further proof of our strong compliance with the Euratom Directive 2013/59 by identifying variations in real time and standardizing and optimizing CT protocols, maintaining gold standards in quality. imaging and increased safety for our patients. By 2023 we have high ambitions to roll out the new version of our Dose Excellence Program in all Affidea countries, guided by our strong commitment to the highest standards of patient safety.”
Theo Kravvas, Country Manager of Affidea Spain, adds: “This is yet another demonstration of the company’s commitment to quality. It is a source of pride and motivation that, both globally and in each country, we all pursue excellence in care and patient safety.”
The awards ceremony took place at Park Westminster Bridge and was attended by over a thousand key figures from the independent healthcare industry.
This award is the second that Affidea has received this year. In June, the company was honored as Diagnostic Provider of the Year at the 2022 HealthInvestor Awards.
About Affidea Group
The Affidea Group (www.affidea.com) is the largest European provider of advanced diagnostic imaging, outpatient and cancer treatment services. It has 329 medical centers in 15 European countries and provides advanced diagnostic, outpatient and cancer treatment services to more than 12 million patients a year. Thanks to its track record in patient safety, Affidea is the most awarded medical imaging service provider in Europe by the European Society of Radiology: more than half of the award-winning centers on the Eurosafe Wall of Stars are Affidea centers.
Affidea Spain
Affidea Spain (www.affidea.es) is a leading medical provider in diagnostic imaging, nuclear medicine and outpatient medical specialties, with 43 centers throughout the country. Affidea Spain performs more than 900,000 diagnostic imaging examinations each year, offering an excellent medical service at the forefront of patient care. The company works with more than 1,100 professionals. Affidea Spain is recognized for its focus on patient safety, having all its centers of excellence in nuclear medicine accredited by the European Union of Medical Specialties (UEMS) and the European Council of Nuclear Medicine (EBNM).
Photo – linkLogo – link
View original content: enlace
